Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: Tagore who wrote (1167)	12/21/1999 6:55:00 PM
From: WTDEC	Respond to of 1972

Tuesday December 21, 3:59 pm Eastern Time Company Press Release Vical Announces That Independent Drug Safety Review Board Recommends Continuation of Allovectin-7 Registration Trials SAN DIEGO--(BUSINESS WIRE)--Dec. 21, 1999--Vical Inc. (Nasdaq:VICL - news) announced today it will continue recruiting patients as planned in two ongoing registration trials with Allovectin-7 in patients with metastatic melanoma, based on the recommendations of an independent Drug Safety Review Board (DSRB). In a single-arm, expanded Phase II trial testing Allovectin-7 in patients with advanced metastatic melanoma, the DSRB concluded that the response rate observed to date warrants continuation of the trial. In both the Phase II trial and in a randomized, controlled Phase III trial, the DSRB found no safety issues to date that would require modification or discontinuation of either trial <snip> biz.yahoo.com

To: Tagore who wrote (1167)	12/23/1999 6:14:00 PM
From: Scott H. Davis	Respond to of 1972

Don't know anything about any HSGI deal, but I do know this stock just hit an all time high. I really like this company - continued progress, straight stuff from mgmt, everything we know about publically continues to move along - just wish the vaccines were moving faster, but VICL can't control it's partner's progress/priorities. Don't remember reading this before the recent release << In addition, the treatment may trigger an immune response against additional tumor cells, both locally and systemically, by enabling the immune system to recognize other features of the tumor cells.>> Also liked this from the release. <<The open-label, multi-center, randomized, controlled Phase III trial is designed to determine the efficacy of Allovectin-7 when combined with standard chemotherapy in patients with unresectable, metastatic melanoma not previously treated with chemotherapy. In prior trials, Allovectin-7 was used only after standard therapies had failed. In the new trial, patients may be enrolled upon diagnosis or upon progression to Stage III or Stage IV disease when surgery or radiation therapy are usually no longer curative. Because Allovectin-7 is intended to trigger an immune response against tumor cells, the company believes the treatment may be more effective in patients whose immune systems have not been compromised. >> Still my favorite biotech. IMSCO Scott